Biotech Most Active Stocks, Affymax, Celsion Corporation, Gilead Sciences, BioMarin Pharmaceutical, VIVUS, Arena Pharmaceuticals, Amgen

Affymax, Inc. (NASDAQ:AFFY) shares rallied 32.48% in last session. In a most recent news Affymax entered into a letter agreement with Lonza Sales Ltd, the Lonza Termination Agreement.  The Lonza agreement dated May 28, 2013, under the term of this deal, both parties have to terminate a Supply Agreement by and between the Company and Lonza, dated September 29, 2008, both the companies have to terminate respective obligations regarding the manufacture and supply of the active ingredient in OMONTYS, and both have to resolve the certain disputes.

In most recent news, Celsion Corporation (NASDAQ:CLSN) announced that it has received commitments from the institutional investors to buy an aggregate of approximately $9.83 million of the Celsion Corporation’s common stock at a per share price of $1.57, this offering was led by a dedicated health care fund.

Its been observed that in clinical studies, the newer formulations from Gilead Sciences, Inc. (NASDAQ:GILD) and J&J show better results with fewer risks.  Hepatitis C, those drug hailed as breakthroughs in 2011, which were made by Johnson & Johnson and Gilead Sciences, will soon be outdated. Hence,  Drug makers are heavily investing hepatitis C research as it become the fastest developing area in medicines, that is what, led the shares of Gilead’s to reach at a record highest level last month.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is seeking US approval of its drug Vimizim previously known as GALNS, it was submitted to the FDA earlier in the year and is used for the treatment of patients suffering from mucopolysaccharidosis type IVA or morquio A syndrome.

The top biotech decliners in last session are, shares of VIVUS, Inc. (NASDAQ:VVUS) retreated -2.58%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) slipped -0.67% and Amgen, Inc. (NASDAQ:AMGN) went down-4.46%.

Affymax, Inc. (NASDAQ:AFFY) advanced 32.48% last trading session and is closed $ 1.57 with average volume 7.29 million shares. Affymax Inc generated income of $ -151.54 million in last twelve months and sales of $ 32.01 million. Analytic Ratios; Price to sales ratio of AFFY in past twelve months was calculated as 1 2.44 and price to cash ratio as 1.45. AFFY return on equity ratio is recorded as -310.34% and its return on assets is -128.10%.

Celsion Corporation (NASDAQ:CLSN) fell -3.98% in last trading session and is closed $ 1.76 with average volume 5.46 million shares. Celsion Corporation generated income of $ -26.57 million in last twelve months. Analytic Ratios; Price to cash ratio of CLSN in past twelve months was calculated as 3.79. CLSN return on equity ratio is recorded as -139.26% and its return on assets -91.60%.

Gilead Sciences, Inc. (NASDAQ:GILD) fell -2.37% in last trading session and is closed $ 55.80 with average volume 12.86 million shares. Gilead Sciences Inc generated income of $ 2.87 billion in last twelve months and sales of $ 9.95 billion. Analytic Ratios; Price to sales ratio of GILD in past twelve months was calculated as 8.35 and price to cash ratio as 42.77. GILD return on equity ratio is recorded as 32.88% and its return on assets is 13.54%.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) fell -1.80% in last trading session and is closed $ 63.85 with average volume 1.35 million shares. BioMarin Pharmaceutical Inc generated income of $ -130.22 million in last twelve months and sales of $ 512.00 billion. Analytic Ratios; Price to sales ratio of BMRN in past twelve months was calculated as 17.02 and price to cash ratio as 21.69. BMRN return on equity ratio is recorded as -12.88% and its return on assets is -8.99%.

VIVUS, Inc. (NASDAQ:VVUS) fell -2.58% in last trading session and is closed $ 15.09 with average volume /2.62 million shares. VIVUS Inc generated income of $ -174.74 million in last twelve months and sales of $ 6.12 million. Analytic Ratios; Price to sales ratio of VVUS in past twelve months was calculated as 241.81 and price to cash ratio as 9.85. VVUS return on equity ratio is recorded as -69.73% and its return on assets is -63.58%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) fell -0.67% in last trading session and is closed $ 8.90 with average volume 6.12 million shares. Arena Pharmaceuticals Inc generated income of $ -77.78 million in last twelve months and sales of $ 27.77 million. Analytic Ratios; Price to sales ratio of ARNA in past twelve months was calculated as 69.33 and price to cash ratio as 14.13. ARNA return on equity ratio is recorded as -124.20% and its return on assets is -36.65%.

Amgen, Inc. (NASDAQ:AMGN) fell -4.46% in last trading session and is closed $ 105.22 with average volume 3.72 million shares. Amgen, Inc generated income of $ 4.60 billion in last twelve months and sales of $ 17.46 billion. Analytic Ratios; Price to sales ratio of AMGN in past twelve months was calculated as 4.32 and price to cash ratio as 3.54. AMGN return on equity ratio is recorded as 23.95% and its return on assets is 9.11%.